-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Compass Therapeutics, Maintains $24 Price Target

Benzinga·04/21/2025 17:35:13
Listen to the news
HC Wainwright & Co. analyst Joseph Pantginis reiterates Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $24 price target.